Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Medical Microbiologists (US)

March 27, 2008
DNAi - early stage excitement
By a GLG Expert Contributor
Analysis of: Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic (www.pipelinereview.com)
DNAi technology, as presented by Pronal Therapeutics provides an exciting opportunity to use this technology as a therapeutic.  PNT2258 may be an important nucleic acid in combating certain types of cancer and solid tumor.  It is an important milestone to have FDA acceptance to begin Phase...
Richard Anthony, PhD, Board member
Richard Anthony, PhD, Board member
Janus Pharmaceuticals, Inc.
July 2, 2007
PDE-5 class effect on Raynauds may provide evidence that SLx-2101 will work
Analysis of: Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease (www.pipelinereview.com)
Viagra (sildenafil) a same a PDE-5 same  class compound as SLx-2101 has shown efficacy for Raynaud's by significantly reducing the frequency and duration of Raynaud attacks and improved capillary flow velocity by 400%, according to a study led by Roland Fries, M.D and published online...

Page : 11 to 2 of 2

Analytics


Generated at 2009-01-07T19:00:58.307